title: n-3, n-6, and n-9 polyunsaturated fatty acids--which composition in parenteral nutrition decreases severity of acute hemorrhagic necrotizing pancreatitis in rats?
abstract: OBJECTIVE
  Acute pancreatitis often requires parenteral nutrition. Thus, we analyzed, using a randomized trial, whether different fatty acids in parenteral nutrition influence lipidperoxidation and histopathology in acute pancreatitis in rats.
  
  
  METHODS
  Seventy-five male Sprague-Dawley rats were randomized into five groups (gr.) (n=15). Gr. 1 underwent a laparotomy followed by saline infusion, gr. 2-5 received intraductal glycodeoxycholic acid (GDOC) followed by intravenous cerulein. Six hours after induction of pancreatitis (IOP), gr. 2 received saline infusion, while gr. 3 was infused with standard lipovenous (rich in [n-6] polyunsaturated fatty acids (PUFA)), gr. 4 received ClinOleic (rich in [n-9] PUFA), while gr. 5 was infused with Omegaven (rich in [n-3] PUFA) for 18 h. After 24 h, all animals were sacrificed and the pancreas was determined histopathologically according to the severity of pancreatitis. Furthermore, pancreatic lipidperoxidation (TBARS) and activity of lipid production protective enzymes superoxide dismutase (SOD) and gluthationperoxidase (GSHPx) were analyzed.
  
  
  RESULTS
  Omegaven infusion reduced the severity of histopathologic changes in acute pancreatitis and decreased lipidperoxidation (TBARS) in pancreatic tissue samples. Furthermore, pancreatic activity of SOD was increased. However, standard PUFA and ClinOleic infusion did not influence the severity of pancreatitis and lipidperoxidation.
  
  
  CONCLUSIONS
  Parenteral nutrition high in n-3 PUFA seems to be superior to compositions of n-6 or n-9 PUFA in the treatment of acute hemorrhagic pancreatitis in rats.
authors.affiliation: Clinic of General, Visceral, Vascular and Thoracic Surgery, Charité Campus Mitte, Humboldt-University of Berlin, Berlin, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kilian
authors.forename: I
authors.initials: I
authors.lastname: Heukamp
authors.forename: J I
authors.initials: JI
authors.lastname: Gregor
authors.forename: C
authors.initials: C
authors.lastname: Bretthauer
authors.forename: M K
authors.initials: MK
authors.lastname: Walz
authors.forename: C A
authors.initials: CA
authors.lastname: Jacobi
authors.forename: H
authors.initials: H
authors.lastname: Lochs
authors.forename: I
authors.initials: I
authors.lastname: Schimke
authors.forename: H
authors.initials: H
authors.lastname: Guski
authors.forename: F A
authors.initials: FA
authors.lastname: Wenger
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D043371:Fatty Acids, Omega-6 / Q000494:pharmacology*; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D010289:Parenteral Nutrition, Total; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012680:Sensitivity and Specificity; D015996:Survival Rate; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
chemical_list: D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D017392:Thiobarbituric Acid Reactive Substances